Literature DB >> 26979057

Determination of Montelukast in Plasma Using β - Cyclodextrins Coated on CoFe2O4 Magnetic Nanoparticles in Luminol-H2O2 Chemiluminescence System Optimized by Doehlert Design.

Abdolraouf Samadi-Maybodi1, Alireza Bakhtiar2, Mohammad Hossein Fatemi2.   

Abstract

A novel chemiluminescence method using β - cyclodextrins coated on CoFe2O4 magnetic nanoparticles is proposed for the chemiluminometric determination of montelukast in plasma. The effect of coated β - cyclodexterinon CoFe2O4 magnetic nanoparticles in the chemiluminescence of luminol-H2O2 system was investigated. It was found that β - cyclodexterin coated on CoFe2O4 magnetic nanoparticles could greatly enhance the chemiluminescence of the luminol-H2O2 system. Doehlert design was applied in order to optimize the number of experiments to be carried out to ascertain the possible interactions between the parameters and their effects on the chemiluminescence emission intensity. This design was selected because the levels of each variable may vary in a very efficient way with few experiments. Doehlert design and response surface methodology have been employed for optimization pH and concentrations of the components. Results showed under the optimized experimental conditions, the relative CL intensity (ΔI) is increased linearly in the concentration range of 0.003-0.586 μgml(-1) of montelukast with limit of detection (LOD) 1.09 × 10(-4) μgml(-1) at S/N ratio of 3, limit of quantitative (LOQ) 3.59 × 10(-4) μgml(-1) and the relative standard deviation 2.63 %. The method has been successfully applied to the determination of montelukast in plasma of human body. Results specified that relative chemiluminescence intensity (ΔI) has good proportional with the montelukast concentration with R(2) = 0.99979. The test of the recovery efficiency for known amounts of montelukast was also performed, the recoveries range obtained from 98.2 to 103.3 %, with RSDs of <4 % indicated that the proposed method was reliable.

Entities:  

Keywords:  Doehlert design; Magnetic nanoparticles; Montelukast; β − cyclodexterin

Mesh:

Substances:

Year:  2016        PMID: 26979057     DOI: 10.1007/s10895-016-1781-8

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  13 in total

Review 1.  The pathophysiology of asthma.

Authors:  Lee Maddox; David A Schwartz
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

2.  Doehlert matrix: a chemometric tool for analytical chemistry-review.

Authors:  Sérgio L C Ferreira; Walter N L Dos Santos; Cristina M Quintella; Benício B Neto; Juan M Bosque-Sendra
Journal:  Talanta       Date:  2004-07-08       Impact factor: 6.057

3.  Voltammetric determination of montelukast sodium in dosage forms and human plasma.

Authors:  I Alsarra; M Al-Omar; E A Gadkariem; F Belal
Journal:  Farmaco       Date:  2005 Jun-Jul

4.  A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children.

Authors:  Naomi Kondo; Toshio Katsunuma; Yasuhei Odajima; Akihiro Morikawa
Journal:  Allergol Int       Date:  2006-09       Impact factor: 5.836

5.  Effects of oral montelukast on airway function in acute asthma.

Authors:  A Cýllý; A Kara; T Ozdemir; C Oğüş; K H Gülkesen
Journal:  Respir Med       Date:  2003-05       Impact factor: 3.415

6.  Simultaneous determination of montelukast as sparing therapy with some inhaled corticosteroids in plasma of asthmatic patients.

Authors:  Sameh Ahmed; Noha N Atia
Journal:  J Pharm Biomed Anal       Date:  2012-11-10       Impact factor: 3.935

7.  Use of magnetic nanoparticles to enhance bioethanol production in syngas fermentation.

Authors:  Young-Kee Kim; Haryeong Lee
Journal:  Bioresour Technol       Date:  2016-01-07       Impact factor: 9.642

8.  Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood.

Authors:  P G Gibson; J W Wlodarczyk; M J Hensley; M Gleeson; R L Henry; A W Cripps; R L Clancy
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

9.  Simultaneous determination of montelukast and fexofenadine using Fourier transform convolution emission data under non- parametric linear regression method.

Authors:  Marwa A A Ragab; Rasha M Youssef
Journal:  J Fluoresc       Date:  2013-06-13       Impact factor: 2.217

10.  Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam; Abdelaaty A Shahat
Journal:  Chem Cent J       Date:  2014-03-11       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.